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Crystallographic Analysis and Mimicking of Estradiol Binding: Interpretation and Speculation http: //dx.doi.org/10.1289/ehp.1307987 In their recent article, Gosavi et al. (2013) presented the results of a crystallographic analy sis of the binding of tetrabromo bisphenol A (TBBPA) and 3hydroxy 2,2´,4,4´tetrabromo diphenyl ether (3OHBDE47) to estrogen sulfotransferase (SULT1E1). The authors demon strated that the tested mole cules fit into the same bind ing pocket as estradiol. However, although the study's methodology and interpreta tion of the crystallographic analysis provide insight into how binding might occur in isolated and in vitro systems, they did not provide evidence that the tested mole cules would initiate any biological activity with the rele vant estrogen receptors (ERs) or pro teins in a human body. For example, the ability of TBBPA to inter act with the ER and estrogenrelated receptors has been evaluated in recombi nant yeast strains, mammalian cell-based assays, and tests developed by the Organisation for Economic Cooperation and Development (Lee et al. 2012; Nakagawa et al. 2007; Ogunbayo et al. 2007 Ogunbayo et al. , 2008 Reistad et al. 2005 Reistad et al. , 2007 Strack et al. 2007 ). Those studies found that TBBPA either did not interact with ERs or that it acted as a weak ER agonist/antagonist with a potency orders of magnitude below that of natural ER ligands. In addition, the data presented by Gosavi et al. (2013) did not include the use of controls to validate the methods. The use of both positive con trols (such as diethylstilbestrol and ethinyl estradiol) and a negative control (such as testosterone) would provide validation of the analysis and allow for the quantifica tion and comparison of the two test sub stances in relation to the binding potentials of the controls.
The authors also speculated about the possible additivity of the various brominated flame retardants and their metabolites and suggested that lowdose exposure to mul tiple lowaffinity binding compounds may result in endocrine disruption. However, none of the data presented directly addressed this point.
It is highly complex, not well under stood, and speculative to extrapolate data on inhibition of enzymes such as SULT1E1 in in vitro assay systems to endocrinesystem modulation of selective gene expression, receptor binding, and activation and the production of adverse effects that would characterize endocrine disruption in vivo by additivity of different chemicals competing on the same receptors. Only through a more complete understanding of target tissue dosimetry, potency of inter action of the chemical of interest with the macro molecule of interest (e.g., SULT1E1), and subsequent events can one address the likelihood of in vivo additivity. Previous studies have addressed the biological effects of brominated flame retar dants (Birnbaum and Staskal 2004; Koike et al. 2013; Mariussen and Fonnum 2003; Ogunbayo et al. 2008) , including a 2year bioassay study performed by the National Toxicology Program (NTP), which demon strated that tetra bromo bisphenol A (TBBPA) can induce aggressive uterine tumors in rats (NTP 2013 (Hamers et al. 2008; Kester et al. 2002; Zhang et al. 1998 ). Our work (Gosavi et al. 2013 ) was focused solely on understanding the struc tural mechanism by which these compounds bind to and inhibit SULT1E1's ability to metabolize estradiol. The results of our work demonstrate that TBBPA and the 3OH metabolite of BDE47, although structur ally different, bind in a simi lar manner at the estradiol binding site. This work suggests that these compounds could have an additive effect on the inhibition of this enzyme. We wholeheartedly agree with Osimitz et al. that the results of our work warrant future studies addressing the potential additive effect of these compounds on steroid metabolism in target tissues.
